PHILADELPHIA - A private Arkansas "illegal extraction" claim against GlaxoSmithKline PLC (GSK) for its marketing of the Avandia diabetes drugs is moot because the state attorney general has already settled identical claims, a Pennsylvania federal judge ruled April 10 in granting the defendant summary judgment (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL Docket No. 1871, No. 07-md-1871, Greg Bowerman v. GlaxoSmithKline LLC, No. 12-3463, E.D. Pa.).